Oura Ring Gen 4 sensor data, not clinical measurementsN=1 case study, not validated for clinical decisionsHEV diagnosed Mar 18; Day 109 post-ruxolitinibMore
Consumer wearable data can support exploratory review only. The HEV diagnosis, temporally confounded with treatment start, remains a material confounder.

Composite Biomarkers

Post-HSCT Monitoring - 31.3 months
ADSI
Elevated
61.2/100
Autonomic Dysfunction | stable (30-day trend)
Autonomic Dysfunction Severity Index. Higher = more dysfunction.
GVHD Score
25.8/100
Wearable Activity | stable (30-day trend)
Composite from HRV, HR, sleep fragmentation, temperature. Ring-derived, not clinical diagnosis.
Recovery
92.7/100
Trajectory Index | stable (30-day trend)
Overall recovery trajectory. Higher = better.
Pharma
3.7Z
Ruxolitinib Response | stable (30-day trend)
Pharmacodynamic response to ruxolitinib. Z-score relative to pre-treatment baseline.
CV Risk
Elevated
49.5/100
Cardiovascular Composite | stable (30-day trend)
Cardiovascular risk proxy from resting HR, HRV, SpO2. Not equivalent to Framingham or SCORE2.
Allostatic
1.0/7
Load Score | stable (30-day trend)
Cumulative physiological stress burden. Scale 0-7.
REPORT SECTION

Summary

Post-HSCT Patient | 31.3 months post-HSCT | Ruxolitinib from 2026-03-16

BiomarkerValueTrend
ADSI61.2/100stable (30-day trend)
GVHD_SCORE25.8/100stable (30-day trend)
RECOVERY_INDEX92.7/100stable (30-day trend)
CV_RISK49.5/100stable (30-day trend)
ALLOSTATIC_LOAD1.0/7stable (30-day trend)
HRV (RMSSD)
Significant
156.7% change
p=0.0000, d=1.76 (large)
Lowest HR
Significant
-17.6% change
p=0.0000, d=1.82 (large)
Average HR
Significant
-15.3% change
p=0.0000, d=1.74 (large)
Sleep Efficiency
Significant
4.2% change
p=0.0000, d=0.66 (medium)
MetricPre-Rux (mean±SD)Post-Rux (mean±SD)Changep-valueCohen's dEffect
HRV (RMSSD)10.0 ± 2.5 ms25.6 ± 11.1 ms+156.7%0.00001.76large
Lowest HR76.7 ± 5.7 bpm63.2 ± 8.3 bpm-17.6%0.00001.82large
Average HR85.2 ± 6.8 bpm72.1 ± 7.8 bpm-15.3%0.00001.74large
Sleep Efficiency78.6 ± 3.4 %81.9 ± 5.7 %+4.2%0.00000.66medium

Three-Period Trajectory

Pre-acute (2026-02-09) → Post-acute/Pre-Rux → Post-Rux (2026-03-16)

HRV (RMSSD): 8.6 ms → 11.2 ms → 25.6 ms (acute event = inflection, Rux stabilized)
Lowest HR: 79.6 bpm → 74.1 bpm → 63.2 bpm (steady improvement)
Average HR: 88.7 bpm → 82.0 bpm → 72.1 bpm (steady improvement)
Sleep Efficiency: 78.1 % → 79.1 % → 81.9 %

Clinical note: The composite ADSI score dilutes these individual metric signals. While ADSI aggregates multiple domains into a single index, individual metrics like HRV and heart rate show statistically significant pre/post differences that the composite score may obscure through averaging.

REPORT SECTION

Biomarker Dashboard